MET and glioblastoma: Consequently, inhibition of MET in GBM mouse models treated by bevacizumab resulted in substantial survival benefit.7 Using a preclinical GBM mouse model, Jun et al. showed that gefinitib inhibition of EGFR resulted in MET overexpression as the most significant transcriptional change (Figure 2A-2).